A novel microcrystalline BAY-876 formulation achieves long-acting antitumor activity against aerobic glycolysis and proliferation of hepatocellular carcinoma
H Yang, MZ Zhang, H Sun, Y Chai, X Li, Q Jiang… - Frontiers in …, 2021 - frontiersin.org
BAY-876 is an effective antagonist of the Glucose transporter type 1 (GLUT1) receptor, a
mediator of aerobic glycolysis, a biological process considered a hallmark of hepatocellular …
mediator of aerobic glycolysis, a biological process considered a hallmark of hepatocellular …
A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity …
JH Wang, Z Zeng, J Sun, Y Chen, X Gao - Pharmacological Research, 2021 - Elsevier
Advanced osteosarcoma (OSA) is highly aggressive and can lead to distant metastasis or
recurrence. Here, a novel small-molecule inhibitor/antagonist of DNA methyltransferase 1 …
recurrence. Here, a novel small-molecule inhibitor/antagonist of DNA methyltransferase 1 …
A novel small-molecule inhibitor of SREBP-1 based on natural product monomers upregulates the sensitivity of lung squamous cell carcinoma cells to antitumor drugs
DB Ma, XY Liu, H Jia, Y Zhang, Q Jiang… - Frontiers in …, 2022 - frontiersin.org
The transcription factor, sterol regulatory element binding protein 1 (SREBP-1), plays
important roles in modulating the proliferation, metastasis, or resistance to antitumor agents …
important roles in modulating the proliferation, metastasis, or resistance to antitumor agents …
Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma
W Zhou, Y Gao, Y Tong, Q Wu, Y Zhou, Y Li - Pharmacological Research, 2021 - Elsevier
Anlotinib is a novel molecular targeted drug that has been approved for the treatment of lung
adenocarcinoma. Currently these agents are rarely used in the treatment of lung squamous …
adenocarcinoma. Currently these agents are rarely used in the treatment of lung squamous …
A novel small molecular inhibitor of DNMT1 enhances the antitumor effect of radiofrequency ablation in lung squamous cell carcinoma cells
YY Liu, CZ Ding, JL Chen, ZS Wang, B Yang… - Frontiers in …, 2022 - frontiersin.org
Radiofrequency ablation (RFA) is a relatively new and effective therapeutic strategy for
treating lung squamous cell carcinomas (LSCCs). However, RFA is rarely used in the clinic …
treating lung squamous cell carcinomas (LSCCs). However, RFA is rarely used in the clinic …
Knockdown of FBI-1 Inhibits the Warburg Effect and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents via miR-3692/HIF-1α
J Liu, C Yang, XM Huang, PP Lv, YK Yang… - Frontiers in …, 2021 - frontiersin.org
The transcription suppressor factor FBI-1 (the factor that binds to inducer of short transcripts-
1) is an important regulator of hepatocellular carcinoma (HCC). In this work, the results …
1) is an important regulator of hepatocellular carcinoma (HCC). In this work, the results …
Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma
Y Jie, G Liu, E Mingyan, Y Li, G Xu, J Guo, Y Li… - European Journal of …, 2021 - Elsevier
The transcription factor ETS-1 (E26 transformation specific sequence 1) is the key regulator
for malignant tumor cell proliferation and invasion by mediating the transcription of the …
for malignant tumor cell proliferation and invasion by mediating the transcription of the …
Novel inhibitor of OCT1 enhances the sensitivity of human esophageal squamous cell carcinoma cells to antitumor agents
X Zou, X Zhou, Y Feng, J Hao, B Liang, M Jia - European Journal of …, 2021 - Elsevier
Esophageal squamous cell carcinoma (ESCC) is one of the most fatal malignancies of the
digestive system, and shows an especially high incidence in some regions of China …
digestive system, and shows an especially high incidence in some regions of China …
miR-27-3p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to the Antitumor Agent Olaparib by Targeting PSEN-1, the Catalytic Subunit of Γ-Secretase
M Zhao, B Sun, Y Wang, G Qu, H Yang… - Frontiers in …, 2021 - frontiersin.org
Olaparib has been used in the treatment of triple-negative breast cancer (TNBC) with BRCA
mutations. In the present study, we demonstrated the effect of miR-27-3p on the γ-secretase …
mutations. In the present study, we demonstrated the effect of miR-27-3p on the γ-secretase …
Novel microcrystal formulations of sorafenib facilitate a long-acting antitumor effect and relieve treatment side effects as observed with fundus microcirculation imaging
J Wang, R Liu, Y Zhao, Z Ma, Z Sang, Z Wen… - Frontiers in …, 2021 - frontiersin.org
The tyrosine kinase inhibitors (TKIs), including sorafenib, remain one first-line antitumor
treatment strategy for advanced hepatocellular carcinoma (HCC). However, many problems …
treatment strategy for advanced hepatocellular carcinoma (HCC). However, many problems …